Hiroshi Hirano Selected Research

Hiroshi Hirano Research Topics

Disease

29	Neoplasms (Cancer) 05/2023 - 03/2002
12	Neoplasm Metastasis (Metastasis) 05/2023 - 03/2002
8	Adenocarcinoma 09/2023 - 07/2003
5	Adenocarcinoma of Lung 12/2021 - 01/2008
5	Carcinoma (Carcinomatosis) 01/2017 - 12/2009
3	Hyperplasia 01/2021 - 09/2002
3	Lung Neoplasms (Lung Cancer) 01/2017 - 07/2003
3	Thymoma (Thymic Carcinoma) 12/2004 - 09/2002
2	Melanoma (Melanoma, Malignant) 03/2023 - 07/2021
2	Lymphatic Metastasis 08/2022 - 04/2003
2	Squamous Cell Carcinoma of Head and Neck 08/2022 - 04/2022
2	Hypopharyngeal Neoplasms 08/2022 - 04/2022
2	Fibrosis (Cirrhosis) 01/2021 - 05/2008
2	Pathologic Constriction (Stenosis) 10/2020 - 12/2012
2	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 07/2003
2	Small Cell Carcinoma 09/2015 - 11/2010
2	Malignant Mesothelioma 06/2014 - 03/2002
2	Neoplasms, Cystic, Mucinous, and Serous 12/2009 - 07/2009
2	Diabetes Complications 02/2007 - 06/2005
2	Insulin Resistance 02/2007 - 06/2005
1	Liver Diseases (Liver Disease) 08/2022
1	COVID-19 07/2022
1	Prurigo 04/2022
1	Glomus Tumor (Glomus Tumors) 12/2021
1	Lipoma (Lipomata) 09/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Idiopathic Noncirrhotic Portal Hypertension 10/2020
1	Aneurysm (Aneurysms) 10/2020
1	Sex Cord-Gonadal Stromal Tumors (Sex Cord-Stromal Tumor) 06/2020
1	Papillary Thyroid Cancer 01/2020
1	Vascular Malformations 03/2019
1	Gallbladder Neoplasms (Gallbladder Cancer) 02/2019
1	Mediastinal Cyst 07/2018
1	Testicular Neoplasms (Testicular Cancer) 01/2017

Drug/Important Bio-Agent (IBA)

5	Cadherins (E-Cadherin)IBA 12/2014 - 12/2009
4	SurvivinIBA 09/2015 - 03/2014
3	Indicators and Reagents (Reagents)IBA 01/2023 - 07/2003
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2007
3	AntigensIBA 01/2017 - 06/2002
3	CateninsIBA 12/2014 - 11/2010
3	Carcinoembryonic AntigenIBA 03/2011 - 06/2002
2	Amylases FDA Link 09/2023 - 03/2011
2	Immune Checkpoint InhibitorsIBA 03/2023 - 01/2017
2	GlucansIBA 03/2023 - 12/2021
2	CytokinesIBA 01/2023 - 12/2021
2	SteroidsIBA 01/2021 - 10/2015
2	Hormones (Hormone)IBA 03/2017 - 07/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2017 - 01/2017
2	VimentinIBA 09/2014 - 06/2002
2	Keratins (Keratin)IBA 03/2011 - 06/2002
2	Monoclonal AntibodiesIBA 09/2002 - 09/2002
1	Periodic AcidIBA 09/2023
1	PerforinIBA 03/2023
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2023
1	PhosphatidylserinesIBA 01/2023
1	Interleukin-12 (IL 12)IBA 01/2023
1	Cisplatin (Platino)FDA LinkGeneric 08/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2022
1	Fluorouracil (Carac)FDA LinkGeneric 08/2022
1	NivolumabIBA 08/2022
1	Cetuximab (Erbitux)FDA Link 08/2022
1	B7-H1 AntigenIBA 08/2022
1	Minocycline (Cyclops)FDA LinkGeneric 04/2022
1	pullulanIBA 12/2021
1	FatsIBA 09/2021
1	AcidsIBA 07/2021
1	ferrous citrate FDA Link 07/2021
1	LigandsIBA 07/2021
1	Estrogen ReceptorsIBA 01/2021
1	Reticulin (Reticular Fiber)IBA 01/2021
1	Phenobarbital (Luminal)FDA Link 01/2021
1	human ERBB2 proteinIBA 01/2021
1	ProteomeIBA 01/2021
1	Thrombopoietin ReceptorsIBA 01/2021
1	Coffee FDA Link 06/2020
1	Inhibins (Inhibin)IBA 06/2020
1	Thyroglobulin FDA Link 01/2020
1	Iodine-131IBA 01/2020
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 02/2019
1	Progesterone Receptors (Progesterone Receptor)IBA 07/2018
1	Histocompatibility Antigens Class IIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017

Therapy/Procedure

11	Therapeutics 03/2023 - 04/2003
4	Immunotherapy 01/2023 - 01/2017
4	Drug Therapy (Chemotherapy) 01/2021 - 08/2004
2	Liver Transplantation 08/2022 - 10/2020
2	Radiotherapy 08/2022 - 12/2019
2	Pancreatectomy 03/2019 - 06/2008
1	Mastectomy (Mammectomy) 05/2023
1	Aftercare (After-Treatment) 03/2023
1	Argon Plasma Coagulation 12/2021
1	Cautery 12/2021
1	Plasmapheresis 01/2021
1	Surgical Splenorenal Shunt (Splenorenal Shunt) 10/2020
1	Ovariectomy (Oophorectomy) 06/2020
1	Neck Dissection (Radical Neck Dissection) 02/2020
1	Hepatectomy 02/2019